Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- Sample size: general considerations
- Sample size calculation
- Sample size example 1
- Sample size example 2
- Group sequential designs
- Fully/group sequential designs
- Group sequential designs example
- Pocock design in detail
- O’Brien-Fleming design in detail
- Alpha-spending function
- How to use alpha-spending function
- Adaptive designs
- Why use adaptive designs?
- What are adaptive designs?
- Adaptive designs basic concepts
- Adaptive designs framework
- Adaptive designs procedures
- Conditional power
- Unconditional power
- Constructing a two-stage design
- More design specifications
- Stage 1
- Conditional power functions
- How to select conditional power functions
- Sample size and critical values for stage 2
- Sample size
- Example: stage 2 sample size
- Example: stage 2 conditional probability
- Example: design characteristics
- Types of specifications
- Concluding remarks
- Thank you
Topics Covered
- General concepts of sample size calculation
- Group sequential designs
- Pocock method
- O'Brien-Fleming method
- Alpha-spending approach
- Adaptive designs
- Pre-specification of design components
- Conditional probabilities
Talk Citation
Koyama, T. (2017, September 28). Frequentist approaches: sample size in adaptive clinical designs [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 26, 2024, from https://doi.org/10.69645/GSEG3512.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Tatsuki Koyama has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Adaptive Clinical Trial Design
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, this is Tatsuki Koyama.
I'm an Associate Professor of Biostatistics at Vanderbilt University School of Medicine.
In this lecture, I'm going to talk about the sample size in adaptive clinical designs.
0:15
And these are the three big topics that I'm going to cover.
0:20
Let's start with general considerations for the sample size in clinical trials,
and these are the single stage conventional designs.
0:31
In general, a large sample size is needed if you want
a small type I error rate and a small type II error rate or a large power,
and these are the things that the investigator chooses.
There are also, a large sample size is required,
when the treatment effect to detect is small,
and one needs to make sure that its critical meaning is no difference,
and the treatment effect reflect the truth.
And then lastly, the large sample size is required when the data variability is large.
And the last two things,
the treatment effect and data variability,
these are the things that you may not have a good idea before the trial begins,
so sometimes, it requires you to have a good guess.
1:25
In the first example,
a new treatment will be compared to
a standard treatment on a survival time using a log-rank test.
And we hypothesize that,
the median survival time under that standard treatment is six months,
and under the new treatment is nine months,
and we set the type I error rate at five percent,
and we set power at 90 percent, that is,
we like to have a 90 percent probability of concluding
efficacy if the new treatment theory really has nine months median survival.
And the sample size calculation shows that we need 137 patients in each group,
and the second line,
which shows the sample size of 102,
is for the power of 80 percent.
In the second sets of numbers, now,
the sample size is at 97 and then 65,
and these are the sample size if the true treatment effect is six months versus 10 months,
instead of six versus nine.
So maybe, this is a motivation
to look at the data and reassess
the sample size based on what you observed in the experiment.